Zydus Lifesciences Ltd

Zydus Lifesciences Ltd

₹ 506 -1.23%
30 May - close price
About

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Key Points

One of the top five pharmaceutical companies in India.[1]

  • Market Cap 51,192 Cr.
  • Current Price 506
  • High / Low 531 / 330
  • Stock P/E 21.5
  • Book Value 173
  • Dividend Yield 1.19 %
  • ROCE 16.6 %
  • ROE 13.8 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 17.8%

Cons

  • The company has delivered a poor sales growth of 7.68% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
3,752 3,515 3,659 3,633 3,670 4,025 3,760 3,640 3,806 4,073 4,135 4,257 5,011
2,961 2,724 2,845 2,866 2,821 3,092 2,860 2,888 3,088 3,240 3,319 3,301 3,755
Operating Profit 791 790 814 766 850 933 900 752 718 833 815 956 1,256
OPM % 21% 22% 22% 21% 23% 23% 24% 21% 19% 20% 20% 22% 25%
-8 38 -70 54 -125 54 2,443 54 64 55 50 39 -566
Interest 82 68 45 27 23 27 30 31 38 34 35 33 28
Depreciation 178 173 175 176 175 183 177 177 185 181 182 182 179
Profit before tax 522 588 524 617 526 777 3,135 598 558 673 648 780 484
Tax % 21% 20% 19% 17% -39% 18% 4% 18% 20% 18% 21% 25% 28%
Net Profit 414 487 435 528 735 642 3,012 511 453 576 526 631 358
EPS in Rs 3.83 4.43 4.62 5.15 6.63 5.74 29.33 4.89 3.88 5.06 5.16 6.15 2.93
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
5,263 6,358 7,224 8,651 9,427 9,376 11,905 13,166 14,253 14,404 15,265 17,237
4,177 5,228 6,021 6,896 7,095 7,474 9,074 10,174 11,455 11,013 11,923 13,378
Operating Profit 1,086 1,130 1,203 1,756 2,332 1,902 2,831 2,991 2,798 3,391 3,342 3,860
OPM % 21% 18% 17% 20% 25% 20% 24% 23% 20% 24% 22% 22%
49 32 30 45 112 127 111 183 -264 -231 2,581 -422
Interest 183 169 90 68 53 45 91 194 342 159 127 130
Depreciation 158 185 201 287 292 373 539 599 696 670 713 723
Profit before tax 794 809 942 1,446 2,099 1,612 2,312 2,382 1,495 2,331 5,084 2,585
Tax % 14% 15% 11% 18% 8% 8% 24% 22% 21% 8% 10% 23%
Net Profit 681 690 836 1,188 1,964 1,517 1,810 1,899 1,204 2,185 4,618 2,092
EPS in Rs 6.37 6.38 7.85 11.24 18.89 14.53 17.35 18.06 11.49 20.84 43.83 19.37
Dividend Payout % 24% 24% 23% 21% 17% 22% 20% 19% 30% 17% 6% 31%
Compounded Sales Growth
10 Years: 10%
5 Years: 8%
3 Years: 7%
TTM: 13%
Compounded Profit Growth
10 Years: 14%
5 Years: 6%
3 Years: 18%
TTM: 8%
Stock Price CAGR
10 Years: 13%
5 Years: 7%
3 Years: 14%
1 Year: 34%
Return on Equity
10 Years: 19%
5 Years: 16%
3 Years: 16%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
102 102 102 102 102 102 102 102 102 102 102 101
Reserves 2,484 2,842 3,337 4,149 5,597 6,858 8,642 10,284 10,273 12,890 16,897 17,415
2,289 2,918 2,700 2,651 2,442 5,207 5,407 7,899 7,986 4,608 4,221 1,195
1,548 1,512 1,847 2,144 2,208 2,937 3,632 4,945 5,115 6,165 6,421 7,046
Total Liabilities 6,423 7,374 7,986 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,756
2,857 3,026 3,124 3,352 3,748 5,755 6,483 12,164 12,230 12,133 12,253 11,591
CWIP 484 736 892 798 951 1,543 1,527 837 742 783 661 1,130
Investments 24 114 87 154 416 435 746 674 765 830 3,288 1,547
3,058 3,498 3,885 4,743 5,235 7,371 9,028 9,556 9,740 10,019 11,439 11,488
Total Assets 6,423 7,374 7,986 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,756

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
511 603 903 994 1,894 1,312 919 1,282 2,932 3,294 2,104 2,689
-1,200 -682 -438 -465 -860 -2,872 -974 -3,977 -1,004 -837 1,137 1,171
860 286 -529 -351 -935 2,316 52 1,885 -1,528 -2,548 -868 -4,400
Net Cash Flow 171 207 -64 178 99 756 -3 -811 399 -90 2,373 -540

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 64 55 57 67 68 89 98 110 94 79 80 94
Inventory Days 234 191 184 175 158 193 211 208 207 246 245 197
Days Payable 117 103 123 125 154 165 167 149 152 168 141 123
Cash Conversion Cycle 181 142 119 118 71 116 142 169 149 158 184 168
Working Capital Days 58 63 46 56 46 62 95 99 79 95 111 108
ROCE % 24% 18% 18% 23% 29% 16% 18% 15% 12% 15% 15% 17%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.98 74.98 74.98
4.56 4.38 5.24 5.23 4.65 4.11 3.79 2.53 2.86 2.61 2.52 3.42
12.59 12.50 11.72 11.30 10.50 11.25 11.80 12.83 11.94 12.86 13.61 13.51
0.19 0.19 0.19 0.19 0.07 0.07 0.07 0.08 0.08 0.07 0.07 0.07
7.78 8.05 7.97 8.40 9.90 9.69 9.46 9.69 10.24 9.47 8.81 8.01

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls